Healthcare systems are no longer navigating a temporary staffing disruption. They are operating within a sustained structural constraint defined by chronic nursing shortages, rising labor costs, and increasing accountability for outcomes across inpatient and outpatient environments. Clinical teams are being asked to manage higher acuity patients with fewer available hours, while financial leaders face mounting pressure to control cost without compromising safety, quality, or access to care.
At the center of this challenge is a workflow that hasn't changed significantly in decades. Manual vital sign collection remains one of the most labor-intensive and structurally embedded responsibilities in healthcare delivery. Nurses spend up to and sometimes in excess of 20% of their shifts measuring and documenting vitals, often on fixed schedules that provide only intermittent insight into patients' conditions. This model consumes scarce clinical capacity while still leaving gaps in visibility that can delay intervention when deterioration begins.
Senphonix was created to address this challenge directly. The SleeveSense platform automates vital sign collection and enables continuous physiological monitoring without adding tasks, devices to manage, or workflows to supervise. Heart rate, respiration, temperature, motion, and in the future, other biosignals, are captured passively, allowing clinicians to maintain visibility into patient status without relying on manual rounds. Monitoring continues seamlessly across inpatient and outpatient settings, supporting safer transitions and extending insight beyond the hospital stay. The result is not simply more data, but more usable time and earlier awareness.
Independent research conducted by MarketWise reinforces the urgency of this model. In a nationwide study of 402 nurses, 98% indicated they saw clear value in automated continuous monitoring and would support adoption of SleeveSense within their healthcare organization. Respondents consistently emphasized that automation, rather than incremental efficiency, is what makes adoption viable in already overextended care environments. Recovered time was viewed as the most meaningful outcome, enabling nurses to focus on assessment, intervention, and patient engagement.
“Manual vitals are not the best use of a nurse’s time anymore. If a system can collect them automatically and reliably, that time goes straight back to patient care, where it belongs.”
"There’s too much that happens between vitals. This would help us intervene earlier."
Financial leaders reached similar conclusions. In a separate national MarketWise study of 457 healthcare finance executives, labor recovery emerged as the most compelling driver of value, followed by readmission avoidance and the ability to support reimbursable remote patient monitoring. These leaders did not view automated monitoring as discretionary technology; they viewed it as operational infrastructure necessary to sustain care delivery amid workforce scarcity and margin compression.
While nursing represents the first point of impact, the implications extend across the healthcare continuum. Continuous, automated monitoring supports earlier detection of deterioration, safer recovery after discharge, and expanded participation in remote patient monitoring reimbursement programs. It enables healthcare systems to scale care capacity without proportional labor expansion and reduces reliance on premium contract staffing.
Over time, this infrastructure can play a critical role in expanding care access in rural and underserved environments, where staffing shortages and geographic barriers make continuous clinical visibility even more essential.
Senphonix delivers monitoring designed to operate invisibly throughout the patient journey, restoring clinical capacity, strengthening financial performance, and improving patient safety without introducing new operational burden.
This is not simply a wearable device. It is a foundational shift in how healthcare systems monitor, protect, and support patients in an era defined by workforce constraint. Take a look at the explainer video below for more context.
“We are not looking for technology that adds capability. We are looking for technology that gives us capacity back. That distinction matters.”
SleeveSense™ will be available upon FDA clearance, which is expected in early 2027.
Senphonix is a Delaware C-Corp., with offices in Minnesota and Arizona. For more information, contact us at info@senphonix.com or 612-913-0607; or follow us on LinkedIn. Copyright © 2026 Senphonix, Inc. - All Rights Reserved. Logos and trademarks are the property of their respective owners. All quotes herein are drawn from anonymous responses to two MarketWise Advising ("MarketWise") national studies, commissioned by Senphonix; some quotes were lightly edited for brevity.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.